Effect of DASH on HF Outcomes Heart Failure Status in Older Adults (DASH HF)
- Disease/Condition
- Heart Failure
- Drug/Device/Intervention
- Dietary Approaches to Stop Hypertension Diet
- Study type
- Interventional
- Intervention type
- other
- Primary sponsor
- University of Georgia
- Location
- Atlanta, United States of America
- Phase
- N/A
- Start date
- Mar 01, 2024
- End date
- Jun 01, 2025
- Enrollment
- 38 participants
B-natriuretic peptide (BNP)
The purpose of this study is to examine the effect of the Dietary Approaches to Stop
 Hypertension (DASH) diet has on heart failure status in older adults. This study is important
 because it may provide a low-cost strategy to help reduce hospitalizations and deaths for
 heart failure patients. Participants will be adults age 65 and older with heart failure. They
 will have 4 study visits, each lasting about 2 hours, and will be in the study for 12 weeks.
 They will also be asked about their dietary consumption 6 times, each time lasting about 45
 minutes. All in-person study visits will take place in the Emory GCRC. Participants will have
 physical exams, body measurements, blood tests, urinalysis, chart review, and answer surveys.
 They will be randomized to eat only the DASH diet provided to them for 4 weeks either at the
 beginning or end of their participation in the study. Participants will be recruited from
 heart failure patients at Emory University Hospital, Emory University Hospital Midtown, and
 Emory Outpatient Advanced Heart Failure Therapy Center. The total enrollment planned under
 Emory's oversight, accounting for screen failures and withdrawals, will be n=38 participants.
 The study team will obtain informed consent prior to the first study visit either in person,
 or, alternatively, over the phone, if requested by participants. Specimens and data obtained
 in this study will not be banked for future use.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06296862
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06296862 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Georgia and is currently Not yet recruiting. The study focuses on Heart Failure. Target enrollment is 38 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.